DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables.

Author(s): Kluft C, Meijer P, LaGuardia KD, Fisher AC

Affiliation(s): Gaubius Laboratory, TNO-Quality of Life, Biomedical Research, Leiden, The Netherlands.

Publication date & source: 2008-02, Contraception., 77(2):77-83. Epub 2008 Jan 11.

Publication type: Research Support, Non-U.S. Gov't

PURPOSE: The aim of this study was to compare effects of the transdermal contraceptive patch, a desogestrel/ethinyl estradiol (EE)-containing, monophasic combination oral contraceptive (COC) and a levonorgestrel/EE-containing, triphasic COC on hemostasis variables. STUDY DESIGN: This was a randomized, open-label study of 104 young women who received six cycles of treatment. Blood was collected at baseline and on treatment; changes by Day 20/Cycle 6 in baseline hemostasis markers [prothrombin fragment 1+2 (F 1+2), plasmin-plasmin inhibitor complex (PAP) and fibrin degradation products (D-dimer)] were assessed. RESULTS: All contraceptives induced similar increases in F 1+2 and D-dimer. Patch-induced PAP increases were less than with the monophasic and similar to the triphasic COC. Decreases in protein S and increases in sex hormone-binding globulin were greater with the patch than with either COC. Patch-induced increases in activated protein C resistance were greater than with the triphasic and similar to the monophasic COC. CONCLUSION: These contraceptives appeared to accelerate baseline procoagulation processes to a similar extent and to change coagulation potency variables differently.

Page last updated: 2008-03-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017